SHPHHealthcare · Drug Manufacturers - Specialty & GenericSHPH Stock Forecast: Shuttle Pharmaceuticals Holdings, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 1 Aug 2026 — in the weakest quartile.
SHPH stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Shuttle Pharmaceuticals Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (98): Smaller than most of the companies we track.
Value (2): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Shuttle Pharmaceuticals Holdings, Inc. — and when they’d sell — is the membership.
SHPH stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SHPH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SHPH analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 38.0×
- Price / sales
- —
- Price / book
- 0.6×
- EV / EBITDA
- −0.1×
Cheaper than 21% of US stocks
Cheaper than 82% of US stocks
Cheaper than 62% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −326.4%
- Return on assets
- −81.7%
- Dividend yield
- —
Higher than 4% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
SHPH vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SHPH appears on the weeks it earns a place.
Frequently asked questions about SHPH stock
How does Ticker Nerd's model rank SHPH?
As at 1 Aug 2026, Shuttle Pharmaceuticals Holdings, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).
What is the SHPH stock forecast for 2030?
No analyst covering Shuttle Pharmaceuticals Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SHPH are extrapolating price history, which says nothing about the business.
How has SHPH stock performed over the past year?
Shuttle Pharmaceuticals Holdings, Inc. returned -90.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Shuttle Pharmaceuticals Holdings, Inc. do?
Shuttle Pharmaceuticals Holdings, Inc. is a biotechnology company dedicated to advancing cancer treatment through innovative therapies.
About Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc. is a biotechnology company dedicated to advancing cancer treatment through innovative therapies. The company's primary focus is on developing proprietary technologies that enhance the efficacy of radiation therapy, which is a critical component of cancer treatment protocols. Shuttle Pharmaceuticals is involved in the research and production of specialized drugs and agents that amplify the therapeutic effects of radiation on tumor cells while minimizing damage to healthy tissues. This approach aims to improve patient outcomes in oncology, offering potential advancements in the treatment of various cancer types. Catering to the healthcare and biotechnology sectors, the company plays a pivotal role in the biomedical field by aiming to elevate standards in cancer care. Shuttle Pharmaceuticals operates within a highly specialized market but holds significant promise given the growing demand for more effective cancer treatments globally.
CEO Mr. Christopher Robert Cooper BBA, M.B.A. · 2 employees · United States · https://www.shuttlepharma.com